Simplex Trading’s Spyre Therapeutics SYRE Stock Holding History

Simplex Trading’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.7K	Buy	+1,100	New	+$80.3K	﹤0.01%	5574
2026 Q1	–	Sell	-33,000	Closed	-$1.08M	–	10124
2025 Q4	$1.08M	Buy	33,000 +22,700	+220%	+$593K	﹤0.01%	2555
2025 Q3	$172K	Buy	10,300 +10,200	+10,200%	+$166K	﹤0.01%	5129
2025 Q2	$1K	Sell	100 -1,000	-91%	-$14.8K	﹤0.01%	8436
2025 Q1	$17K	Buy	+1,100	New	+$22.9K	﹤0.01%	6723
2022 Q2	–	Sell	-36	Closed	-$2K	–	11067
2022 Q1	$2K	Sell	36 -112	-76%	-$9.4K	﹤0.01%	9934
2021 Q4	$17K	Buy	148 +92	+164%	+$14.5K	﹤0.01%	8565
2021 Q3	$9K	Hold	56	–	–	﹤0.01%	9008
2021 Q2	$9K	Buy	+56	New	+$10.2K	﹤0.01%	9173
2021 Q1	–	Hold	0	–	–	–	8397
2019 Q4	–	Sell	-1	Closed	-$19K	–	7949
2019 Q3	$19K	Buy	+1	New	+$195	﹤0.01%	5852

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Simplex Trading's SYRE Position: Q2 2026 in Review

Simplex Trading opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 278 shares worth $24.7K. The stake represents ﹤0.01% of the portfolio and ranks #6917 among its holdings. This is a return to the name: Simplex Trading previously reported a position in SYRE as recently as Q2 2025.

Simplex Trading first reported a position in SYRE in Q2 2019 and has held it in 16 quarters since. 267 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Simplex Trading held 278 shares of Spyre Therapeutics worth $24.7K as of Q2 2026.
Spyre Therapeutics was a new Simplex Trading position in Q2 2026.
Spyre Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6917 holding.
Simplex Trading first reported a position in Spyre Therapeutics in Q2 2019 and has held it in 16 quarters since.
267 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.